British alliance on ninja antibodies
Enlarge image


British alliance on ninja antibodies

03.04.2012 - London companies PolyTherics and Spirogen collaborate for better antibody-drug-conjugates (ADCs) in the fight against cancer.

London – The buzz around antibody-drug-conjugates (ADCs), the weapons of choice in the fight against cancer, just became more blatant. After last week’s news that a novel ADC company had been founded in Switzerland PolyTherics Limited from London (UK) announced on 2 April that it would join in the treasure hunt for promising ADC candidates. Just like the Swiss ADC Therapeutics Sarl, London-seated PolyTherics relies on the cytotoxic agents provided by Spirogen Limited. The two companies want to combine PolyTherics’ linker technology TheraPEG™ with Spirogen’s potent cytotoxic pyrrolobenzodiazepines („PBDs“). The aim is to connect PBDs via the new linker to antibodys or antibody fragments in a site-specific manner. PolyTherics CEO John Burt is enthusiastic: „This is an exciting opportunity to combine our validated conjugation technology with Spirogen’s potentially best-in-class PBD warheads.“ Also Spirogen CEO Chris Martin is convinced the collaboration will bear fruit: „ADCs will represent a significant medical breakthrough in cancer therapy. PolyTherics’ TheraPEG™ conjugation technology will broaden the applications where our PBD warheads and linkers can create highly potent potentially market-leading ADC candidates.“ Spirogen’s PBDs are DNA minor groove binding agents, which bind and cross-link specific DNA-sites. They block cell division in the targeted (cancer) cells without distorting their DNA helix, thus avoiding the common phenomenon of emergent drug resistance.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD46.1%
  • CELLECTIS (F)30.70 EUR32.8%


  • EPIGENOMICS (D)1.87 EUR-58.6%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5266.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR255.9%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 25.11.2015